GlassScriptPhysician profile
Frances Clark
NPI 1689602468
$2,187.47
in general payments reported to CMS, 2019-2025
25 companies · $799 in 2025
The $799 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $244 · 2022: $383 · 2023: $487 · 2024: $274 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,560.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $431.43 | 2022-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.32 | 2021-2022 | |
| Glaxosmithkline, LLC. | $179.86 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $157.34 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $141.19 | 2021-2025 | |
| Baxter Healthcare | $119.65 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mylan Specialty L.P. | $116.55 | 2021-2023 | Yupelri |
| Mallinckrodt Hospital Products INC. | $111.30 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $109.67 | 2024-2025 | Purified Cortrophin Gel |
| Takeda Pharmaceuticals U.S.A., INC. | $76.53 | 2022-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $65.29 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $63.19 | 2023-2025 | Dupixent |
| Amgen INC. | $63.07 | 2025 | Tezspire |
| United Therapeutics Corporation | $49.81 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $48.29 | 2023-2025 | Winrevair |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $41.70 | 2025 | Zepbound |
| Inogen, INC. | $39.71 | 2023-2025 | Inogen At Home Stationary Concentrator |
| Pulmonx Corporation | $33.33 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Philips North America LLC | $32.49 | 2023-2025 | Vest Therapy Und |
| Insmed, INC. | $30.72 | 2022-2023 | Arikayce |
| Pfizer INC. | $18.58 | 2024 | |
| Avadel Cns Pharmaceuticals, LLC | $17.30 | 2023 | Lumryz |
| Janssen Pharmaceuticals, INC | $17.25 | 2021 | |
| Chiesi USA, INC. | $16.76 | 2025 | Cleviprex, Kengreal |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.